D-0037-2026 Class II Ongoing
FDA drug recall D-0037-2026 was initiated by Graviti Pharmaceuticals Private Limited on Sep 15, 2025 and is designated Class II. Reason for recall: Failed Tablet/Capsule Specifications The recall status is ongoing. Affected quantity: 46,512/30 count bottles.
Recall details
- Product Type
- Drugs
- Report Date
- Oct 29, 2025
- Initiation Date
- Sep 15, 2025
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 46,512/30 count bottles
Product description
Bupropion Hydrochloride Extended-Release Tablets USP (XL), 300 mg, 30-count bottles, Rx Only, Mfd. by: Graviti Pharmaceuticals Private Limited, Sangareddy, Telangana, India, Dist. by: Rising Phar, NDC 16571-863-03.
Reason for recall
Failed Tablet/Capsule Specifications
Distribution pattern
Product was distributed to 1 distributor and 16 wholesalers/pharmacy retailers nationwide.
Code information
Batch # BPB124341A, Exp date: 10/2026
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0037-2026
- openFDA file date
- Nov 16, 2026
- Loaded by RegDataLab
- Nov 17, 2026